skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Highlights in this white paper include:

Understanding competitor drug development strategies is critical to maximizing R&D investment. While looking at the number of drugs in development in competitors’ pipelines is a good starting point, much more granular analyses are needed to fully understand what is happening in the industry, and with competitors, specifically. This paper provides insights into which companies are sponsoring cancer trials, using data from Citeline’s Trialtrove® and Pharmaprojects® Pipeline®.


  • A breakdown of industry-sponsored oncology trials begun between 2006-2010
  • Trends in industry-sponsored trials started in low resource countries
  • A look at trial activity by geographic area at the company level to assess competitive experience by region
  • Phase II and III oncology trials started with first-line patients over a five-year period

Factors contributing to country selection and patient segment, and what the trial counts show 
access competitor trials whitepaper

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: